The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Open accessAbstract
The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from “normal” cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease‐modifying therapies may be most efficacious.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The susceptibility of the conventional criteria for MCI to diagnostic error is likely to be amplified if used to characterize and stage preclinical AD—a pre-MCI categorization based on subtle cognitive decline [8].”
From Neuropsychological Criteria for Mild Cognitive Impairment Improves Diagnostic Precision, Biomarker Associations, and Progression Rates (2014) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In PET imaging, PIB and Florbetapir (AV45) amyloid tracers have shown greater cortical uptake in patients diagnosed with AD compared with control participants 11,57 .”
From OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease (2019) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several anti-Aβ therapeutic strategies are being pursued to treat AD; however, it is likely that treatment will need to begin during the preclinical phase to prevent or limit plaque accumulation to be beneficial in reducing the risk of developing AD (51, 52).”
From Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans (2011) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New clinical diagnostic consensus criteria have now been finalized under the auspices of the NIA and Alzheimer's Association (52), with novel features including recognition of a preclinical stage of AD and the incorporation of imaging and laboratory-based cerebrospinal fluid biomarkers.”
From Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 (2012) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alzheimer’s disease (AD) begins several decades before the clinical onset of dementia with progressive amyloid accumulation preceding significant tau pathology and neurodegeneration.10,11”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [11]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Because there is evidence that the pathophysiology of AD likely begins many years before the emergence of clinical symptoms or a syndrome such as MCI or dementia”
From The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features (2017) · cites this paper as [102]
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, after decades of research, both the etiology and the pathophysiologic sequence of AD remain uncertain [102]”
From The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features (2017) · cites this paper as [102]
The cited source says what the claim attributes to it.
In the citing paper
“This unifying research framework is a natural descendant of the 2011 NIA-AA preclinical AD recommendations that were based on the concept that AD, identified by biomarkers, can exist in the absence of symptoms [4].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Clinico-pathologic correlations for individuals without cognitive impairment should indicate that it is possible for AD neuropathologic change to predate onset of symptoms by years [54].”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“recognition that AD neuropathologic changes may occur in the apparent absence of cognitive impairment”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“This later point is important as the pathophysiological changes in the brain of people with AD require several years to occur.16”
From Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study (2015) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“The timing of therapeutic treatment in AD seems to be crucial as studies have shown that treating the disease too late has little efficacy (Sperling et al., 2011; Yiannopoulou et al., 2019).”
From Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model (2022) · cites this paper as Sperling et al., 2011
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“But their high cost and insufficient accessibility are being major limitations [12].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“individuals remain cognitively normal for many years despite accumulating aggregates of Aβ plaques and tau neurofibrillary tangles (Sperling et al., 2011).”
From A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease (2017) · cites this paper as Sperling et al., 2011
In the citing paper
“The neuropathological changes of Alzheimer’s disease (AD) begin two decades or more before signs of cognitive impairment (Sperling et al., 2011).”
From A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease (2017) · cites this paper as Sperling et al., 2011
In the citing paper
“Additionally, we used the old criteria for the preclinical AD definition, while the recent research criteria also require tau positivity [8].”
From Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype (2019) · cites this paper as [8]
In the citing paper
“Plaque formation rates also vary over time [217]. After a period of rapid accumulation, plaque deposition gradually slows and by the time symptoms manifest plaque deposition is essentially done [20, 205, 218].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [20]
In the citing paper
“The amyloid cascade hypothesis [14, 15], in conjunction with the newly designated preclinical AD category [20], necessarily infers cognitive changes that arise before plaques appear are etiologically unrelated to cognitive changes that arise after plaques appear.”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [20]
In the citing paper
“In addition to using Aβ phenomena to distinguish AD from “normal” brain aging, the new criteria make one critical mechanistic assumption. Aβ is identified as an “upstream” AD biomarker [77]. Other biomarkers, including increased CSF tau, CSF phospho-tau, and decreased glucose utilization (as demonstrated by fluorodeoxyglucose PET; FDG PET), are identified as “downstream” biomarkers.”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“According to the new AD diagnostic criteria cognitive decline and an absence of alternative dementia-associated pathology are no longer required features. At least for research purposes, to qualify for a diagnosis of AD altered brain or CSF Aβ is now the sole requirement [77].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“This is reflected by the recent adoption of AD diagnostic criteria that classify cognitively normal individuals with brain plaques or low cerebrospinal fluid Aβ levels as having “preclinical AD” [77].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“Studies of non-demented elderly cohorts overall report approximately 20–40% are PIB-positive [67, 68, 71–78].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“According to the new criteria, the primary dividing line between AD and brain aging is the presence or absence of brain or CSF Aβ changes.”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“This asymptomatic phase of AD (AsymAD) is currently considered a preclinical stage of the disease [27, 28].”
From Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease (2018) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“ries [68]) and the clinical syndrome of AD dementia (estimated prevalence from three epidemiological studies [69–71]).”
BackgroundAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms.”
BackgroundSelf-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationAlzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Stern, Y. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2009.03.004 · Cited by 2,943
Self-citationDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationJack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042
Self-citation
Research works printed but not linked: 1
- JABecker DRentz JSCarmasin THedden IHamdi RLBuckner et al.Amyloid deposition and brain volume across the continuum of aging and AD.Ann Neurol2011(in press)
Cited by
Sorted by citations
Items 801–900 of 1,158
Alzheimer’s disease and language impairments: social intervention and medical treatment
Kuca, K., Maresova, P., Klimova, B., Valis, M., & Hort, J. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s89714 · Cited by 122
Harmonized diagnostic criteria for Alzheimer's disease: recommendations
Morris, J. C., Blennow, K., Froelich, L., Nordberg, A. K., Soininen, H. S., Waldemar, G., Wahlund, L., & Dubois, B. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12199 · Cited by 122
Plasma amyloid‐β and risk of Alzheimer's disease in the Framingham Heart Study
Chouraki, V. A., Beiser, A., Younkin, L. H., Preis, S. R., Weinstein, G., Hansson, O., Skoog, I. G., Lambert, J., Au, R., Launer, L. J., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.07.001 · Cited by 122
Recommendations of the Alzheimer's Disease–Related Dementias Conference
Montine, T. J., Koroshetz, W. J., Babcock, D., Dickson, D. W., Galpern, W. R., Glymour, M. M., Greenberg, S. M., Hutton, M. L., Knopman, D. S., Kuzmichev, A. N., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000733 · Cited by 122
Self-citationEarly diagnosis and treatment of Alzheimer’s disease: new definitions and challenges
Pais, M. V., Martinez, L. D., Ribeiro, O. G., Loureiro, J. C., Fernandez, R., Valiengo, L. D. C. L., Canineu, P. R., Stella, F., Talib, L. L., Radanovic, M., et al. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0735 · Cited by 124
Long-term Dietary Flavonoid Intake and Subjective Cognitive Decline in US Men and Women
Yeh, T., Yuan, C., Ascherio, A., ROSNER, B. A., Willett, W. C., & Blacker, D. (2021) · Neurology · doi:10.1212/wnl.0000000000012454 · Cited by 122
Staging of Alzheimer’s disease: past, present, and future perspectives
Therriault, J., Zimmer, E. R., Benedet, A. L., Pascoal, T. A., Gauthier, S. G., & Rosa‐Neto, P. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.05.008 · Cited by 123
Depressive Symptoms and Biomarkers of Alzheimer’s Disease in Cognitively Normal Older Adults
Donovan, N. J., Hsu, D. C., Dagley, A. S., Schultz, A. P., Amariglio, R. E., Mormino, E. C., Okereke, O. I., Rentz, D. M., Johnson, K. A., Sperling, R. A., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142940 · Cited by 122
Self-citationTracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging
Zimmer, E. R., Leuzy, A., Benedet, A. L., Breitner, J., Gauthier, S., & Rosa-Neto, P. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-120 · Cited by 121
Reduced cerebrovascular reactivity in young adults carrying the APOE ε4 allele
Suri, S., Mackay, C. E., Kelly, M. E., Germuska, M. A., Tunbridge, E. M., Frisoni, G. B., Matthews, P. M., Ebmeier, K. P., Bulte, D. P., & Filippini, N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.05.1755 · Cited by 122
Manook, A., Yousefi, B. H., Willuweit, A., Platzer, S., Reder, S., Voß, A., Huisman, M. C., Settles, M., Neff, F., Velden, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031310 · Cited by 121
Detectable Neuropsychological Differences in Early Preclinical Alzheimer’s Disease: A Meta-Analysis
Han, S. D., Nguyen, C. P., Stricker, N. H., & Nation, D. A. (2017) · Neuropsychology Review · doi:10.1007/s11065-017-9345-5 · Cited by 121
Nowrangi, M. A., Lyketsos, C. G., Leoutsakos, J. S., Oishi, K., Albert, M., Mori, S., & Mielke, M. M. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.05.2186 · Cited by 120
Henderson, B. W., Gentry, E. G., Rush, T., Troncoso, J. C., Thambisetty, M., Montine, T. J., & Herskowitz, J. H. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13688 · Cited by 120
Self-citationGenetically modified pig models for neurodegenerative disorders
Holm, I. E., Alstrup, A. K. O., & Luo, Y. (2015) · The Journal of Pathology · doi:10.1002/path.4654 · Cited by 120
Frota, N. A. F., Nitríni, R., Damasceno, B. P., Forlenza, O. V., Dias‐Tosta, E., da Silva, A. B., Herrera, E., & Magaldi, R. M. (2011) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642011dn05030002 · Cited by 120
Targeting Cognitive Frailty: Clinical and Neurobiological Roadmap for a Single Complex Phenotype
Panza, F., Seripa, D., Solfrizzi, V., Tortelli, R., Greco, A., Pilotto, A., & Logroscino, G. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150358 · Cited by 120
Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change
Soldan, A., Pettigrew, C. A., Cai, Q., Wang, M., Moghekar, A., O’Brien, R., Selnes, O. A., & Albert, M. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0194 · Cited by 120
Paasila, P. J., Davies, D., Kril, J. J., Goldsbury, C. S., & Sutherland, G. T. (2019) · Brain Pathology · doi:10.1111/bpa.12717 · Cited by 120
Winston, C. N., Goetzl, E. J., Schwartz, J. B., Elahi, F. M., & Rissman, R. A. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.11.002 · Cited by 120
Wu, J., Zhang, X., Azhati, G., Li, T., Xu, G., & Liu, F. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14381 · Cited by 120
Hippocampal Subfield Volumetry and 3D Surface Mapping in Subjective Cognitive Decline
Perrotin, A., de Flores, R., Lamberton, F., Poisnel, G., La Joie, R., de la Sayette, V., Mézenge, F., Tomadesso, C., Landeau, B., Desgranges, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150087 · Cited by 119
Tayeb, H. O., Murray, E. D., Price, B. H., & Tarazi, F. I. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.789856 · Cited by 119
Ultrastructural evidence of microglial heterogeneity in Alzheimer’s disease amyloid pathology
El Hajj, H., Savage, J. C., Bisht, K., Parent, M., Vallières, L., Rivest, S., & Tremblay, M.-È. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1473-9 · Cited by 119
Aging alters neural activity at event boundaries in the hippocampus and posterior medial network
Reagh, Z. M., Delarazan, A. I., Garber, A., & Ranganath, C. (2020) · Nature Communications · doi:10.1038/s41467-020-17713-4 · Cited by 119
Diagnosis and management of Alzheimer's disease: Past, present and future ethical issues
Gauthier, S. G., Leuzy, A., Racine, É., & Rosa‐Neto, P. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.01.003 · Cited by 119
Alzheimer’s disease CSF biomarkers: clinical indications and rational use
Niemantsverdriet, E., Valckx, S., Bjerke, M., & Engelborghs, S. (2017) · Acta Neurologica Belgica · doi:10.1007/s13760-017-0816-5 · Cited by 119
Ge, Y., Xu, W., Ou, Y., Qu, Y., Ma, Y., Huang, Y., Shen, X., Chen, S.-D., Tan, L., Zhao, Q., et al. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101361 · Cited by 119
Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years
Albert, M., Zhu, Y., Moghekar, A., Mori, S., Miller, M. I., Soldan, A., Pettigrew, C., Selnes, O., Li, S., & Wang, M.-C. (2018) · Brain · doi:10.1093/brain/awx365 · Cited by 118
Derby, C. A., Burns, L. C., Wang, C., Katz, M. J., Zimmerman, M. E., L’Italien, G., Guo, Z., Berman, R., & Lipton, R. B. (2013) · Neurology · doi:10.1212/wnl.0b013e31828ab2c9 · Cited by 118
Harrington, M. G., Chiang, J., Pogoda, J. M., Gomez, M. E., Thomas, K., Marion, S., Miller, K. J., Siddarth, P., Yi, X., Zhou, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079378 · Cited by 118
Epigenetics: A novel therapeutic approach for the treatment of Alzheimer's disease
Adwan, L. I., & Zawia, N. H. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.03.010 · Cited by 118
Using Machine Learning to Predict Dementia from Neuropsychiatric Symptom and Neuroimaging Data
Gill, S., Initiative, A. D. N., Mouchès, P., Hu, S., Rajashekar, D., MacMaster, F. P., Smith, E. E., Forkert, N. D., & Ismail, Z. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191169 · Cited by 118
Body mass index and cognitive function: the potential for reverse causation
Suemoto, C. K., Gilsanz, P., Mayeda, E. R., & Glymour, M. M. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.83 · Cited by 118
Huijbers, W., Vannini, P., Sperling, R. A., Pennartz, C. M. A., Cabeza, R. E. L., & Daselaar, S. M. (2012) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2012.08.021 · Cited by 118
Self-citationSchultz, S. A., Oh, J. M., Koscik, R. L., Dowling, N. M., Gallagher, C. L., Carlsson, C. M., Bendlin, B. B., LaRue, A., Hermann, B. P., Rowley, H. A., et al. (2015) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2014.11.010 · Cited by 117
In vivo characterization of the early states of the amyloid-beta network
Sepulcre, J., Sabuncu, M. R., Becker, A., Sperling, R., & Johnson, K. A. (2013) · Brain · doi:10.1093/brain/awt146 · Cited by 117
Self-citationKincheski, G. C., Valentim, I. S., Clarke, J. R., Cozachenco, D., Castelo-Branco, M. T. L., Ramos-Lobo, A. M., Rumjanek, V. M. B. D., Donato, J., De Felice, F. G., & Ferreira, S. T. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.04.007 · Cited by 117
O'Dwyer, L., Lamberton, F., Bokde, A. L. W., Ewers, M., Faluyi, Y. O., Tanner, C., Mazoyer, B., O'Neill, D., Bartley, M., Collins, D. R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032441 · Cited by 117
Korecka, M., Waligórska, T., Figurski, M., Toledo, J. B., Arnold, S. E., Grossman, M., Trojanowski, J. Q., & Shaw, L. M. J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132489 · Cited by 117
The Role of microRNAs in Alzheimer’s Disease and Their Therapeutic Potentials
Shaik, M. M., Tamargo, I. A., Abubakar, M. B., Kamal, M. A., Greig, N. H., & Gan, S. H. (2018) · Genes · doi:10.3390/genes9040174 · Cited by 117
Dhiman, K., Blennow, K., Zetterberg, H., Martins, R. N., & Gupta, V. B. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03040-5 · Cited by 117
Wilcockson, T. D. W., Mardanbegi, D., Xia, B., Taylor, S., Sawyer, P., Gellersen, H. W., Leroi, I., Killick, R., & Crawford, T. J. (2019) · Aging · doi:10.18632/aging.102118 · Cited by 117
Gómez‐Ramírez, J., Ávila‐Villanueva, M., & Fernández‐Blázquez, M. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-77296-4 · Cited by 118
Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease
Sperling, R. A., Henley, D. B., Aisen, P. S. S., Raman, R., Donohue, M., Ernstrom, K. B., Rafii, M. S., Streffer, J. R., Shi, Y., Karcher, K., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.4857 · Cited by 117
Self-citationLim, Y. Y., Jaeger, J., Harrington, K., Ashwood, T., Ellis, K. A., Stöffler, A., Szoeke, C. E. I., Lachovitzki, R., Martins, R. N., Villemagne, V. L., et al. (2013) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/act021 · Cited by 117
Self-citationLopez Lopez, C., Tariot, P. N., Caputo, A., Langbaum, J. B., Liu, F., Riviere, M., Langlois, C., Rouzade‐Dominguez, M., Zalesak, M., Hendrix, S., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.02.005 · Cited by 116
Self-citationSoldan, A., Pettigrew, C. A., Lu, Y., Wang, M., Selnes, O. A., Albert, M., Brown, T., Ratnanather, J. T., Laurent Younes, B., & Miller, M. I. (2015) · Human Brain Mapping · doi:10.1002/hbm.22810 · Cited by 116
Burnham, S. C., Faux, N. G., Wilson, W. J., Laws, S. M., Ames, D. J., Bedő, J., Bush, A. I., Doecke, J. D., Ellis, K. A., Head, R. J., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.40 · Cited by 116
Self-citationMeta-analysis of functional network alterations in Alzheimer's disease: Toward a network biomarker
Jacobs, H. I. L., Raduà, J., Lückmann, H. C., & Sack, A. T. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.03.009 · Cited by 116
Jie, B., Zhang, D., Chong-yaw Wee, A., & Shen, D. G. (2013) · Human Brain Mapping · doi:10.1002/hbm.22353 · Cited by 116
Nabers, A., Ollesch, J., Schartner, J., Kötting, C., Genius, J., Hafermann, H., Klafki, H., Gerwert, K. B., & Wiltfang, J. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b04286 · Cited by 116
Gispert, J. D., Suárez‐Calvet, M., Monté, G. C., Tucholka, A., Falcón, C., Rojas, S., Rami, L., Sánchez‐Valle, R., Lladó, A., Kleinberger, G., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.005 · Cited by 116
Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies
Lue, L., Guerra, A., & Walker, D. G. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0074-8 · Cited by 116
Clinical application of next-generation sequencing to the practice of neurology
Rexach, J. E., Lee, H., Martínez-Agosto, J. A., Nemeth, A. H., & Fogel, B. L. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30033-x · Cited by 117
Vissers, M. F. J. M., Heuberger, J. A. A. C., Groeneveld, G. J., Nijhuis, J. O., Deyn, P. P. D., Hadi, S., Harris, J. M., Tsai, R. M., Cruz-Herranz, A., Huang, F., et al. (2022) · Clinical and Translational Science · doi:10.1111/cts.13317 · Cited by 116
Kumar, V., Kim, S.-H., & Bishayee, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179540 · Cited by 116
Ewers, M., Brendel, M., Rizk‐Jackson, A., Rominger, A., Bartenstein, P., Schuff, N. W., & Weiner, M. W. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.10.018 · Cited by 116
Wennström, M., Surova, Y., Hall, S., Nilsson, C., Minthon, L., Hansson, O., & Nielsen, H. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135458 · Cited by 116
The therapeutics of Alzheimer's disease: Where we stand and where we are heading
Selkoe, D. J. (2013) · Annals of Neurology · doi:10.1002/ana.24001 · Cited by 116
Facilitating Alzheimer Disease Research Recruitment
Grill, J. D., & Galvin, J. E. (2013) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000016 · Cited by 115
Perturbations of neural circuitry in aging, mild cognitive impairment, and Alzheimer's disease
Leal, S. L., & Yassa, M. A. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.01.006 · Cited by 114
Zygouris, S., Ntovas, K., Giakoumis, D., Votis, K., Doumpoulakis, S., Segkouli, S., Karagiannidis, C., Tzovaras, D. K., & Tsolaki, M. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160518 · Cited by 115
Stocker, H. R., Beyer, L., Trares, K., Perna, L., Rujescu, D., Holleczek, B., Beyreuther, K. T., Gerwert, K. B., Schöttker, B., & Brenner, H. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.52387 · Cited by 116
Bangen, K. J., Beiser, A., Delano‐Wood, L., Nation, D. A., Lamar, M., Libon, D. J., Bondi, M. W., Seshadri, S. S., Wolf, P. A., & Au, R. (2013) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2013.03.013 · Cited by 115
Wolfsgruber, S., Polcher, A., Koppara, A., Kleineidam, L., Frölich, L., Peters, O., Hüll, M., Rüther, E., Wiltfang, J., Maier, W., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161252 · Cited by 114
Progress in Alzheimer’s disease
Galimberti, D., & Scarpini, E. A. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6145-3 · Cited by 114
Belleville, S., Fouquet, C., Duchesne, S., Collins, D. L., & Hudon, C. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141470 · Cited by 114
Speech and language impairments in dementia
Klímová, B., & Kamil, K. (2016) · Journal of Applied Biomedicine · doi:10.1016/j.jab.2016.02.002 · Cited by 114
Functional Disintegration of the Default Mode Network in Prodromal Alzheimer’s Disease
Dillen, K. N. H., Jacobs, H. I. L., Kukolja, J., Richter, N., von Reutern, B., Onur, O. A., Langen, K., & Fink, G. R. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161120 · Cited by 114
Precision pharmacology for Alzheimer’s disease
Hampel, H. J., Vergallo, A., Aguilar, L. F., Benda, N., Broich, K., Cuello, A. C., Cummings, J. L., Dubois, B., Federoff, H. J., Fiandaca, M. S., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.014 · Cited by 114
The Cortical Neuroanatomy Related to Specific Neuropsychological Deficits in Alzheimer's Continuum
Kang, S. H., Park, Y. H., Lee, D., Kim, J. P., Chin, J., Ahn, Y., Park, S. B., Kim, H. J., Jang, H., Jung, Y. H., et al. (2019) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2019.18.3.77 · Cited by 114
Gibson, G. E., Luchsinger, J. A., Cirio, R. T., Chen, H., Franchino‐Elder, J., Hirsch, J. A., Bettendorff, L., Chen, Z., Flowers, S. A., Gerber, L. M., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200896 · Cited by 114
Self-citationFrantzidιs, C. A., Vivas, A. B., Tsolaki, A., Klados, M. A., Tsolaki, M., & Bamidis, P. D. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00224 · Cited by 114
Alzheimer's disease including focal presentations
Villain, N., & Dubois, B. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1681041 · Cited by 113
Baldacci, F., Lista, S., Cavedo, E., Bonuccelli, U., & Hampel, H. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1304217 · Cited by 113
Predicting conversion from MCI to AD with FDG-PET brain images at different prodromal stages
Cabral, C., Morgado, P. M., Costa, D. C., & Silveira, M. (2015) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2015.01.003 · Cited by 113
Rembach, A., Watt, A. D., Wilson, W. J., Rainey‐Smith, S. R., Ellis, K. A., Rowe, C. C., Villemagne, V. L., Macaulay, S. L., Bush, A. I., Martins, R. N., et al. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.05.005 · Cited by 113
Self-citationA rapid and cost-effective method for genotyping apolipoprotein E gene polymorphism
Zhong, L., Xie, Y.-Z., Cao, T.-T., Wang, Z., Wang, T., Li, X., Shen, R.-C., Xu, H., Bu, G., & Chen, X. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0069-4 · Cited by 113
Imaging of neuroinflammation in dementia: a review
Stefaniak, J. D., & O'Brien, J. T. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-311336 · Cited by 113
Olsen, R. K., Yeung, L., Noly‐Gandon, A., D’Angelo, M. C., Kacollja, A., Smith, V. M., Ryan, J. D., & Barense, M. D. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.04.025 · Cited by 113
Perneczky, R., Kempermann, G., Korczyn, A. D., Matthews, F. E., Ikram, M. A., Scarmeas, N., Chételat, G., Stern, Y., & Ewers, M. (2019) · BMC Medicine · doi:10.1186/s12916-019-1283-z · Cited by 114
Self-citationHoffman, J. L., Faccidomo, S., Kim, M., Taylor, S. M., Agoglia, A. E., May, A. M., Smith, E. N., Wong, L. C., & Hodge, C. W. (2019) · International review of neurobiology · doi:10.1016/bs.irn.2019.10.017 · Cited by 113
Devos, H., Gustafson, K. M., Ahmadnezhad, P., Liao, K., Mahnken, J. D., Brooks, W. M., & Burns, J. M. (2020) · Brain Sciences · doi:10.3390/brainsci10120994 · Cited by 115
Fontaine, D., Deudon, A., Lemaire, J., Razzouk, M., Viau, P., Darcourt, J., & Robert, P. H. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121579 · Cited by 113
VETSA: The Vietnam Era Twin Study of Aging
Kremen, W. S., Franz, C. E., & Lyons, M. J. (2012) · Twin Research and Human Genetics · doi:10.1017/thg.2012.86 · Cited by 113
Werner, P., Goldstein, D., Segel‐Karpas, D., Chan, L. C. K., & Lai, C. K. Y. (2014) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000065 · Cited by 113
Timmers, M., Streffer, J. R., Russu, A., Tominaga, Y., Shimizu, H., Shiraishi, A., Tatikola, K., Smekens, P., Börjesson-Hanson, A., Andreasen, N., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0415-6 · Cited by 112
The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment
Tosto, G., Zimmerman, M. E., Hamilton, J. L., Carmichael, O. T., Brickman, A. M., & Initiative, A. D. N. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.014 · Cited by 112
Shah, R. C., Kamphuis, P. J., Leurgans, S., Swinkels, S. H., Sadowsky, C. H., Bongers, A., Rappaport, S. A., Quinn, J. F., Wieggers, R. L., Scheltens, P., et al. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt224 · Cited by 112
Self-citationBemelmans, S. A. S. A., Tromp, K., Bunnik, E. M., Milne, R., Badger, S. J., Brayne, C., Schermer, M., & Richard, E. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0212-z · Cited by 112
Silverberg, N. B., Elliott, C. L., Ryan, L. M., Masliah, E., & Hodes, R. J. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.03.004 · Cited by 112
Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease
Cohen, A. D., Landau, S. M., Snitz, B. E., Klunk, W. E., Blennow, K., & Zetterberg, H. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.12.004 · Cited by 112
Nogueras‐Ortiz, C. J., Mahairaki, V., Delgado‐Peraza, F., Das, D., Avgerinos, K. I., Eren, E., Hentschel, M. B., Goetzl, E. J., Mattson, M. P., & Kapogiannis, D. (2020) · Cells · doi:10.3390/cells9071618 · Cited by 112
Hermida, A. P., McDonald, W. M., Steenland, K., & Levey, A. I. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.127 · Cited by 112
MRI and MRS predictors of mild cognitive impairment in a population-based sample
Kantarci, K., Weigand, S. D., Przybelski, S. A., Preboske, G. M., Pankratz, V. S., Vemuri, P., Senjem, M. L., Murphy, M. C., Gunter, J. L., Machulda, M. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31829a3329 · Cited by 112
Self-citationLaurent Younes, B., Albert, M., & Miller, M. I. (2014) · NeuroImage Clinical · doi:10.1016/j.nicl.2014.04.009 · Cited by 111
Papp, K. V., Amariglio, R. E., Dekhtyar, M., Roy, K., Wigman, S. E., Bamfo, R., Sherman, J. B., Sperling, R. A., & Rentz, D. M. (2014) · The Clinical Neuropsychologist · doi:10.1080/13854046.2014.911351 · Cited by 111
Self-citationHarada, R., Okamura, N., Furumoto, S., Tago, T., Maruyama, M., Higuchi, M., Yoshikawa, T., Arai, H., Iwata, R., Kudo, Y., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2261-2 · Cited by 111
Logue, M. W., Panizzon, M. S., Elman, J. A., Gillespie, N. A., Hatton, S. N., Gustavson, D. E., Andreassen, O. A., Dale, A. M., Franz, C. E., Lyons, M. J., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0030-8 · Cited by 111
Metadata
- Authors
- Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison‐Bogorad, M., Wagster, M. V., & Phelps, C. H.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California San Diego (US)
- University of California, Davis (US)
- Rush University Medical Center (US)
- University of Washington (US)
- Washington University in St. Louis (US)
- The University of Tokyo (JP)
- Mayo Clinic (US)
- Oregon Health & Science University (US)
- The University of Texas at Dallas (US)
- Banner Alzheimer’s Institute (US)
- The University of Melbourne (AU)
- Eli Lilly (United States) (US)
- Columbia University Irving Medical Center (US)
- San Francisco VA Medical Center (US)
- Alzheimer's Association Chicago IL USA
- Alzheimer's Association (US)
- National Institutes of Health (US)
- Corresponding author
- Sperling, Reisa A.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2011-04-22
- Volume
- 7
- Issue
- 3
- Pages
- 280-292
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC3220946
- OpenAlex
- W2129497119
- Semantic Scholar
- 4718e61de2c928d77780b2a72fac704f18d8297b
- Cited by
- 7,155
- References
- 71
- Citations by year
- 2026: 375 · 2025: 467 · 2024: 485 · 2023: 445 · 2022: 534 · 2021: 575 · 2020: 550 · 2019: 533 · 2018: 513 · 2017: 471 · 2016: 468 · 2015: 461 · 2014: 417 · 2013: 418 · 2012: 302
- FWCI
- 277.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Columbia Academic Commons (Columbia University)
- Funders
- National Institute on Aging
- Pfizer
- Baxter International
- Johnson and Johnson
- Eli Lilly and Company
- Bayer
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, preclinical Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Cognition Disorders, Humans, United States, Biomarkers, Practice Guidelines as Topic, National Institute on Aging (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
